Market & Industry Briefs
Executive Summary
Brief summaries of recent medtech market and industry developments. This month we cover what might be inhaled insulin's death knell, MetaCure's play in interventional diabetes and Novartis' deal with Alcon, and the US fracture fixation market.
You may also be interested in...
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover MannKind's positive inhaled insulin results, Medtrnoic's acquisition of CryoCath, Allergan's positive migraine results, and a new large-scale trial to assess late-stent thrombosis.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover MannKind's positive inhaled insulin results, Medtrnoic's acquisition of CryoCath, Allergan's positive migraine results, and a new large-scale trial to assess late-stent thrombosis.
MetaCure Ushers in a New Era in Interventional Diabetes
Welcome to the new world of interventional diabetes. Based on new data, institutions offering gastric bypass surgeries for weight loss are now recasting them as treatments for type 2 diabetes. This is a dramatic change in perspective within the drug-oriented diabetology world. Now MetaCure hopes to take that interventional notion a step further, with a minimally-invasive and reversible therapy based on electrical stimulation applied to the stomach.